Riot Blockchain (RIOT) 10-Q 13 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 13, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Riot Blockchain, Inc.
Entity Central Index Key	1,167,419
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,017
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		8,321,137

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets (Note 1):
Cash and cash equivalents	$ 13,139,722	$ 5,529,848
Short-term investments		7,506,761
Prepaid expenses and other current assets	295,059	219,991
Current assets of discontinued operations (Note 9)	11,532	486,890
Total current assets	13,446,313	13,743,490
Property and equipment, net (Note 3)	4,113	5,538
Investment in Coinsquare (Note 2)	3,000,000
Other long term assets, net (Note 4)	899,319	938,038
Noncurrent assets of discontinued operations (Note 9)		2,353,749
Total assets	17,349,745	17,040,815
Current liabilities:
Accounts payable	248,820	253,817
Accrued compensation	4,659	1,520
Accrued expenses	122,990	304,675
Notes and other obligations, current portion (Note 5)	215,712	139,611
Deferred revenue, current portion (Note 8)	96,698	96,698
Current liabilities of discontinued operations (Note 9)	202,080	258,819
Total current liabilities	890,959	1,055,140
Deferred revenue, less current portion (Note 8)	992,792	1,065,316
Total liabilities	1,883,751	2,120,456
Commitments and contingencies (Notes 6, 8 and 10)
Stockholders' equity (Notes 6 and 7):
Preferred Stock, no par value, 15,000,000 (2017) and 0 (2016) shares authorized; 2,000,000 (2017) and 0 (2016) shares designated as 2% Series A Convertible Stock, 19,194.72 shares issued and outstanding (2017)	4,798,671
Common stock, no par value, 170,000,000 (2017) and 60,000,000 (2016) shares authorized; shares issued and outstanding 5,447,792 (2017) and 4,503,971 (2016)	131,490,219	124,775,635
Accumulated deficit	(120,822,896)	(109,855,276)
Total stockholders' equity	15,465,994	14,920,359
Total liabilities and stockholders' equity	$ 17,349,745	$ 17,040,815

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Preferred stock, par value
Preferred stock, shares authorized	15,000,000	0
Preferred stock, shares issued	19,195	0
Preferred stock, shares outstanding	19,195	0
Common stock, par value
Common stock, shares authorized	170,000,000	60,000,000
Common stock, shares issued	5,447,792	4,503,971
Common stock, shares outstanding	5,447,792	4,503,971
Designated as 2% Series A Convertible Stock [Member]
Preferred stock, shares authorized	2,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Other revenue - fee (Note 8)	$ 24,175	$ 24,175	$ 72,524	$ 72,524
Operating expenses:
Selling, general and administrative	597,018	1,480,141	2,694,211	3,333,102
Research and development	17,658	52,963	63,008	498,634
Total operating expenses	614,676	1,533,104	2,757,219	3,831,736
Operating loss from continuing operations	(590,501)	(1,508,929)	(2,684,695)	(3,759,212)
Other income (expense):
Gain on property and equipment sale (Note 3)		13,062		1,933,335
Interest expense	(4,773,397)	(2,384)	(4,802,296)	(28,130)
Investment income	30,903	23,639	83,247	103,031
Total other income (expense)	(4,742,494)	34,317	(4,719,049)	2,008,236
Loss from continuing operations	(5,332,995)	(1,474,612)	(7,403,744)	(1,750,976)
Discontinued operations (Note 9):
Income (loss) from operations	30,922	(236,473)	(944,557)	(236,473)
Escrow forfeiture gain (Note 6)			134,812
Impairment (loss)			(2,754,131)
Total income (loss) from discontinued operations	30,922	(236,473)	(3,563,876)	(236,473)
Net loss	$ (5,302,073)	$ (1,711,085)	$ (10,967,620)	$ (1,987,449)
Basic and diluted net income (loss) per share (Note 1)
Continuing operations	$ (0.99)	$ (0.37)	$ (1.47)	$ (0.45)
Discontinued operations	0.01	(0.06)	(0.71)	(0.06)
Basic and diluted net loss per share (Note 1)	$ (0.98)	$ (0.43)	$ (2.18)	$ (0.51)
Basic and diluted weighted average number of shares outstanding (Note 1)	5,401,552	3,999,637	5,037,764	3,918,151

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - 9 months ended Sep. 30, 2017 - USD ($)	Preferred Stock	Common Stock [Member]	Accumulated Deficit	Total
BALANCE at Dec. 31, 2016		$ 124,775,635	$ (109,855,276)	$ 14,920,359
BALANCE, shares at Dec. 31, 2016		4,503,971
Private placement of Common Stock (Note 6)		$ 1,913,509		1,913,509
Private placement of Common Stock (Note 6), shares		900,000
Common Shares in escrow forfeited and retired (Note 6)		$ (134,812)		(134,812)
Common Shares in escrow forfeited and retired (Note 6), shares		(32,801)
Equity rights redemption (Note 6)		$ (291,995)		(291,995)
Equity rights redemption (Note 6), shares
Discount on Convertible Debt arising from values of (Note 6):
Warrants		$ 2,325,151		2,325,151
Beneficial conversion feature		2,424,849		2,424,849
Preferred Stock issued upon Notes payable conversion (Note 6)	$ 4,798,671			4,798,671
Preferred Stock issued upon Notes payable conversion (Note 6), shares	19,195
Exercise of stock options		$ 98,260		$ 98,260
Exercise of stock options, shares		34,000		34,000
Stock-based compensation issued for services		$ 379,622		$ 379,622
Stock-based compensation issued for services, shares		42,622
Net loss for the period			(10,967,620)	(10,967,620)
BALANCE at Sep. 30, 2017	$ 4,798,671	$ 131,490,219	$ (120,822,896)	$ 15,465,994
BALANCE, shares at Sep. 30, 2017	19,195	5,447,792

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Continuing operations:
Net (loss)	$ (10,967,620)	$ (1,987,449)
(Loss) from discontinued operations	(3,563,876)	(236,473)
(Loss) from continuing operations	(7,403,744)	(1,750,976)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities of continuing operations:
Amortization of discount on convertible debt	4,750,000
Stock-based compensation for services	379,622	368,459
Depreciation and amortization	55,899	74,098
Amortization of license fees	(72,524)	(72,524)
Other non-cash (credits) charges		200,108
Gain on sale of property and equipment		(1,933,335)
Change in:
Prepaid expenses and other current assets	192,071	222,474
Accounts payable	(4,997)	(483,410)
Accrued compensation	3,139	(120,775)
Accrued expenses	(133,014)	30,042
Net cash (used in) operating activities of continuing operations	(2,233,548)	(3,465,839)
Net cash (used in) operating activities of discontinued operations	(930,323)	(375,228)
Net cash (used in) operating activities	(3,163,871)	(3,841,067)
Continuing operations:
Purchases of short-term investments		(13,818,949)
Proceeds from sales of short-term investments	7,506,761	16,522,853
Investment in Coinsquare	(3,000,000)
Proceeds from sale of property and equipment		1,799,143
Purchases of patent and trademark application costs	(14,255)	(14,378)
Net cash provided by investing activities of continuing operations	4,492,506	4,488,669
Net cash provided by investing activities of discontinued operations	4,004	16,673
Net cash provided by investing activities	4,496,510	4,505,342
Continuing operations:
Net proceeds from issuance of convertible notes	4,750,000
Net proceeds from issuance of common stock, net of $336,491 in offering expenses	1,913,509
Net proceeds from exercise of stock options	98,260
Redemption of equity rights	(291,995)
Repayment of notes payable and other obligations	(192,539)	(229,238)
Net cash provided by (used in) financing activities of continuing operations	6,277,235	(229,238)
Net increase in cash and cash equivalents	7,609,874	435,037
Cash and cash equivalents at beginning of period	5,529,848	2,012,283
Cash and cash equivalents at end of period	13,139,722	2,447,320
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	1,571	33,331
Supplemental disclosure of noncash investing and financing activities:
Conversion of notes payable and accrued interest to preferred stock	4,798,671
Liability payoffs upon property sale		$ 2,064,758

Consolidated Statements of Cas7

Consolidated Statements of Cash Flows (Parenthetical)	9 Months Ended
	Sep. 30, 2017USD ($)
Statement of Cash Flows [Abstract]
Payment of offering expenses	$ 336,491

INTERIM FINANCIAL STATEMENTS

INTERIM FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
INTERIM FINANCIAL STATEMENTS	INTERIM FINANCIAL STATEMENTS The accompanying consolidated financial statements of Riot Blockchain, Inc., (f/k/a Bioptix, Inc.) (the "Company," "we," or "Riot Blockchain") have been prepared in accordance with the instructions to quarterly reports on Form 10-Q. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and changes in financial position at September 30, 2017 and for all periods presented have been made. Certain information and footnote data necessary for fair presentation of financial position and results of operations in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted. It is therefore suggested that these consolidated financial statements be read in conjunction with the summary of significant accounting policies and notes to financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2016. The results of operations for the period ended September 30, 2017 are not necessarily an indication of operating results for the full year. Effective October 19, 2017, the Company's name was changed to Riot Blockchain, Inc., from Bioptix, Inc. Management's plans and basis of presentation: The Company has experienced recurring losses and negative cash flows from operations. At September 30, 2017, the Company had approximate balances of cash and cash equivalents of $13,140,000, working capital of $12,555,000, total stockholders' equity of $15,466,000 and an accumulated deficit of $120,823,000. To date, the Company has in large part relied on equity financing to fund its operations. The recently announced Kairos”), Tess, Inc., (“TESS”) and acquisitions, as well as our new name, reflect a new focus (in addition to veterinary and life science oriented businesses of the Company) being pursued by the Company. The decision to invest in companies exposed to blockchain and digital currency related risks is a strategic decision by the Company. The Company’s strategy will be to continue to pursue opportunistic investments and controlling positions in these new and emerging technologies which will continue to expose the Company to the numerous risks and volatility associated with this sector. Effective January 14, 2017, the Company adopted a plan to exit the business of BiOptix Diagnostics, Inc. ("BDI") and commenced a significant reduction in the workforce. The decision to adopt this plan was made following an evaluation by the Company's Board of Directors in January 2017, of the estimated results of operations projected during the near to mid-term period for BDI, including consideration of product development required and updated sales forecasts, and estimated additional cash resources required. Accordingly, the historical results of BDI have been classified as discontinued operations for all periods presented. The Company expects to continue to incur losses from operations for the near-term and these losses could be significant as we incur costs and expenses associated with our recent and potential future acquisitions and investments, as well as public company and administrative related expenses are incurred and winding-down BDI’s operations. The Company believes its upcoming near-term cash needs relative to the recent acquisitions will be covered by cash acquired in the acquisitions combined with the Company’s available cash. The Company believes that its current working capital position will be sufficient to meet its estimated cash needs for at least a year and a day from this filing. The Company is closely monitoring its cash balances, cash needs and expense levels. Management's strategic plans include the following: • continuing to evaluate opportunities for investments in the blockchain and digital currency sector; • exploring other possible strategic options and financing opportunities available to the Company; • evaluating options to monetize, partner or license the Company's assets, including the appendicitis product portfolio; and • continuing to implement cost control initiatives to conserve cash.

Significant accounting policies

Significant accounting policies	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Significant accounting policies	Note 1. Significant accounting policies: Principles of consolidation The consolidated financial statements of the Company include the accounts of Riot Blockchain and its wholly-owned subsidiary, BDI. Intercompany accounts and transactions have been eliminated in the consolidation. Investment in affiliate The Company’s 10.9% investment in Coinsquare is accounted for on the cost method. Cash, cash equivalents and short-term investments: The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company's cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. The Company invests excess cash from time to time in highly-liquid debt and equity investments of highly-rated entities, which are classified as trading securities. Such amounts are recorded at market values using Level 1 inputs in determining fair value and are generally classified as current, as the Company does not intend to hold the investments beyond twelve months. Investment securities classified as trading are those securities that are bought and held principally for the purpose of selling them in the near term, with the objective of preserving principal and generating profits. These securities are reported at fair value with unrealized gains and losses reported as an element of other (expense) income in current period earnings. The Company's Board of Directors has approved an investment policy covering the investment parameters to be followed with the primary goals being the safety of principal amounts and maintaining liquidity. The policy provides for minimum investment rating requirements as well as limitations on investment duration and concentrations. Based upon market conditions, the investment guidelines have been tightened to increase the minimum acceptable investment ratings required for investments and shorten the maximum investment term. As of September 30, 2017, 100% of the investment portfolio was in cash and cash equivalents, which is presented as such on the accompanying balance sheet. The Company's short-term investments comprise certificates of deposit, commercial paper and corporate bonds, all of which are classified as trading securities and carried at their fair value based upon quoted market prices of the securities at December 31, 2016. Net realized and unrealized gains and losses on trading securities are included in net loss. For purposes of determining realized gains and losses, the cost of securities sold is based on specific identification. The composition of trading securities is as follows at December 31, 2016: December 31, 2016 Cost Fair Value Certificates of deposit / commercial paper $ 2,378,222 $ 2,373,891 Corporate bonds 5,138,182 5,132,870 Total trading securities $ 7,516,404 $ 7,506,761 Investment income for the nine months ended September 30, 2017 and 2016 consists of the following: 2017 2016 Interest income $ 84,177 $ 101,236 Realized (losses) (21 ) (2,893 ) Unrealized gains 11,575 21,501 Management fee expenses (12,484 ) (16,813 ) Net investment income $ 83,247 $ 103,031 Fair value of financial instruments: The Company accounts for financial instruments under Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic ("ASC") 820, Fair Value Measurements Level 1— quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 — observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 — assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company's market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. There were no financial assets or liabilities measured at fair value, with the exception of short-term investments as of December 31, 2016. The carrying amounts of the Company's financial instruments (other than short-term investments as discussed above) approximate fair value because of their variable interest rates and/or short maturities combined with the recent historical interest rate levels. Revenue Recognition: Revenue recognition related to the license agreement is based upon the licensee's right to use the technology and the Company's ongoing obligations to maintain and defend the patented rights and comply with the terms of the sub-license agreement whereby the license fees and milestone payments received from the agreement, net of the amounts due to third parties, have been recorded as deferred revenue and are amortized over the term of the license agreement. Goodwill: The Company performs a goodwill impairment analysis in the fourth quarter of each year, or whenever there is an indication of impairment. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation to determine if it is more likely than not that the fair value of its reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a two-step goodwill impairment test. The Company has determined, based on its evaluation, that the goodwill associated with the BDI acquisition was impaired and was written off during the nine months ended September 30, 2017, included as part of the discontinued operations impairment loss. Recently issued and adopted accounting pronouncements: The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company's financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company's consolidated financial statements properly reflect the change. In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update No. 2014-09, Revenue from Contracts with Customers In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows In January 2017, the FASB issued an ASU 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) In May 2017, the FASB issued ASU No. 2017-09, "Compensation-Stock Compensation: Scope of modification accounting". ASU 2017-09 provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU No. 2017-09 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted, including during an interim period for which financial statements have not yet been made available for issuance. The amendments should be applied prospectively to an award modified on or after the adoption date. The Company is currently evaluating the impact that the adoption of ASU 2017-09 will have on its consolidated financial statements. In July 2017, the FASB issued ASU No. 2017-11, "Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815)," which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements. Income (loss) per share: ASC 260, Earnings Per Share Basic net income (loss) per share includes no dilution and is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding for the period, excluding any nonvested restricted common shares. Diluted net income (loss) per share reflect the potential dilution of securities that could share in the Company's income (loss). The effect of the inclusion of the dilutive shares would have resulted in a decrease in loss per share for the periods ended September 30, 2017 and 2016. Outstanding stock options, warrants and other dilutive rights are not considered in the calculation, as the impact of the potential common shares (totaling approximately 5,474,000 shares and 1,061,000 shares for each of the nine month periods ended September 30, 2017 and 2016, respectively) would be anti-dilutive. For the nine months ended September 30, 2017 the dilutive rights not considered in the calculation, include shares of Series A Convertible Preferred Stock (“Series A Preferred Stock”) outstanding that are convertible into 1,919,472 common shares. For periods when shares of preferred stock are outstanding, the two-class method is used to calculate basic and diluted earnings (loss) per common share since such preferred stock is a participating security under ASC 260 Earnings per Share. Under the provisions of ASC 260, "Earnings Per Share," basic EPS shall be computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Income available to common stockholders shall be computed by deducting both the dividends declared in the period on preferred stock and the dividends accumulated for the period on cumulative preferred stock from income from continuing operations. Dividends during the nine months ended September 30, 2017 were de minimis

Investment in Coinsquare

Investment in Coinsquare	9 Months Ended
	Sep. 30, 2017
Investments, All Other Investments [Abstract]
Investment in Coinsquare	Note 2. Investment in Coinsquare: As of September 29, 2017, the Company acquired a minority interest for $3,000,000 USD, in Coinsquare, which operates a digital crypto-currency exchange platform operating in Canada. The Company acquired approximately 10.9% of the voting common stock of Coinsquare. In connection with the investment, the Company also received warrants, expiring May 30, 2018, to acquire shares of common stock of Coinsquare, which if exercised in full by the Company, would result in the Company owning an approximate total of 14.7% of Coinsquare, including the initial investment. The fair value of the warrants were determined to be de minimis. Investments – Other

Property and equipment

Property and equipment	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property and equipment	Note 3. Property and equipment: Property and equipment consisted of the following: September 30, 2017 December 31, 2016 Office and computer equipment $ 114,309 $ 116,510 Less accumulated depreciation 110,196 110,972 $ 4,113 $ 5,538 Depreciation expense totaled approximately $500 and $800, and $1,400 and $2,700, for the three and nine month periods ended September 30, 2017 and 2016, respectively. Depreciation and amortization expenses also included $1,500 and $12,000, for the nine month periods ended September 30, 2017 and 2016, respectively, on short-term assets included with prepaid expenses. On February 25, 2016, the Company completed the sale of its corporate headquarters, land, building and certain fixtures and equipment to a third party for a purchase price of approximately $4,053,000. The sale and subsequent equipment sales resulted in a gain of approximately $1,933,000 and generated approximately $1,799,000 in net cash after expenses and mortgage payoffs.

Other long-term assets

Other long-term assets	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Other long-term assets	Note 4. Other long-term assets: Other long-term assets consisted of the following as of September 30, 2017 and December 31, 2016: Beginning Balance (December 31, 2016) Additions Impairments Ending Balance (September 30, 2017) Cost: Patents $ 1,032,982 $ 14,255 $ — $ 1,047,237 Goodwill 447,951 — — 447,951 Total 1,480,933 14,255 — 1,495,188 Accumulated Amortization: Patents (482,183 ) (52,974 ) — (535,157 ) Goodwill (60,712 ) — — (60,712 ) Total (542,895 ) (52,974 ) — (595,869 ) Net Other Long Term Assets $ 938,038 $ (38,719 ) $ — $ 899,319 The Company capitalizes legal costs and filing fees associated with obtaining patents on its new discoveries. Once the patents have been issued, the Company amortizes these costs over the shorter of the legal life of the patent or its estimated economic life using the straight-line method. Based upon the current status of the above intangible assets, the aggregate amortization expense is estimated to be approximately $71,000 for each of the next five fiscal years. The Company tests intangible assets with finite lives for impairment upon significant changes in the Company's business environment. The testing resulted in no patent impairment for the three and nine months ended September 30, 2017 and $32,000 and $200,000, for the three and nine months ended September 30, 2016, respectively. The impairment charges are related to the Company's ongoing analysis of which specific country patents in its portfolio are determined as potentially worth pursuing.

Notes and Other Obligations

Notes and Other Obligations	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Notes and Other Obligations	Note 5. Notes and Other Obligations: Notes and other obligations consisted of short-term installment obligations, arising from insurance premium financing programs bearing interest at approximately 4.5%, with outstanding balances of $215,712 and $139,611, as of September 30, 2017 and December 31, 2016, respectively. Convertible notes: In March 2017, the Company completed a convertible note financing with certain accredited investors with gross proceeds totaling $4,750,000. The convertible notes bearing interest at 2% were issued March 16, 2017 and had a balloon payment maturity date of September 16, 2018, when any then outstanding principal and accrued interest, would be due. The unsecured notes were convertible into shares of the Company’s common stock at the holder’s option or automatically into shares of preferred stock, upon achievement of defined conditions, including shareholder approval of a class of preferred stock, all at an initial conversion price of $2.50 (initially 1,900,000 common shares). In connection with the financing investors were issued warrants exercisable into a total of 1,900,000 common shares at an exercise price of $3.56, expiring March 15, 2020. The convertible note financing proceeds were held in escrow pending successful completion of defined release conditions. As of August 18, 2017, the lead investor in the convertible note financing, agreed to waive the release conditions and the cash proceeds and securities were released from escrow. Subsequently, upon the successful completion of conditions specified in the offering documents, and as further described in Note 6, the notes automatically converted into shares of Series A Preferred Stock. The convertible notes accrued interest at 2% per annum commencing with their execution and the Company recorded interest expense of $48,671 through the date of conversion, which was also exchanged for shares of preferred stock. See Note 6. Mortgage notes: Prior to the February 2016 sale of the corporate headquarters, the Company had a permanent mortgage on its land and building. The mortgage was held by a commercial bank and included a portion guaranteed by the U. S. Small Business Administration ("SBA"). The loan was collateralized by the real property and the SBA portion was also personally guaranteed by a former officer of the Company. The commercial bank loan terms included a payment schedule based on a fifteen year amortization, with a balloon maturity at five years. The commercial bank portion had an interest rate fixed at 3.95%, and the SBA portion bore interest at the rate of 5.86%. On February 25, 2016, the Company completed the sale of its corporate headquarters, land and building, and also paid off its mortgage obligations. See Note 3.

Stockholders' equity

Stockholders' equity	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Stockholders' equity	Note 6. Stockholders' equity: Articles of Incorporation amendments: Effective September 19, 2017, the Company changed its state of incorporation from Colorado to Nevada (the “Reincorporation”). In connection with the Reincorporation and as approved by the Company’s shareholders at a special meeting held August 21, 2017 Special Shareholders’ Meeting, the Company’s Articles of Incorporation were amended to increase the number of shares of common stock authorized for issuance to 170,000,000 from 60,000,000. Additionally, the Articles of Incorporation were amended to authorize 15,000,000 shares of “blank check” preferred stock. On September 20, 2017, 2,000,000 shares of preferred stock were designated as “2% Series A Convertible Preferred Stock” in connection with the filing of a Certificate of Designation of Rights, Powers, Preferences, Privileges and Restrictions of 2% Series A Convertible Preferred Stock with the Secretary of State of the State of Nevada. Common Share Private Placement offering: In March 2017, the Company completed a common stock unit financing private placement totaling $2,250,000, with certain accredited investors. The purchase price was $2.50 per unit (the “Units”). Each Unit consisted of one share of the Company's common stock and a three-year warrant to purchase one share of the Company's common stock at an exercise price of $3.50 per share. The fair value of the 900,000 warrants was estimated to be approximately $2,114,000, using the Black-Scholes option-pricing model using the assumptions of a three year term, expected price volatility of 114%, dividend yield of 0% and a risk free interest rate of 1.66%. The Company sold 900,000 units consisting of an aggregate of 900,000 shares of common stock and 900,000 warrants, of which 400,000 units for $1,000,000 were released to the respective parties in March 2017, and the balance of 500,000 units for $1,250,000 were released in May 2017. The offering net of $336,491 of offering expenses, resulted in proceeds of $1,913,509 recorded as additional equity. In connection with the private placements, the Company also entered into a Registration Rights Agreement, with the investors as further disclosed with the convertible note private placement offering described below. Convertible Note Private Placement offering: In March 2017, the Company completed a 2% convertible note financing with certain accredited investors with gross proceeds totaling $4,750,000. The convertible note financing proceeds were held in escrow pending successful completion of defined release conditions. As of August 18, 2017, the lead investor in the convertible note financing, agreed to waive the release conditions and the cash proceeds and securities were released from escrow. Upon the successful completion of conditions specified in the offering documents, primarily approval by the Company’s shareholders for authorization of preferred shares and approval of the Nasdaq Capital Market (“NASDAQ”), the notes automatically converted into shares of Series A Preferred Stock, convertible into shares of common stock at an initial equivalent conversion price of $2.50 per common share. The specified conditions were successfully completed as of September 20, 2017, resulting in the conversion of $4,750,000 in principal and accrued interest of $48,671 for a total of $4,798,671 worth of convertible notes, exchanged for 19,194.72 shares of Series A Preferred Stock, with a stated value of $250 per share, equaling rights to 1,919,472 shares of common stock. The convertible notes accrued interest at 2% per annum commencing with their execution and the Company recorded interest expense of $48,671 through the date of conversion of the notes. The Series A Preferred Stock are convertible into shares of common stock based on a conversion calculation equal to the stated value ($250.00 per share) of such shares of Series A Preferred Stock, plus all accrued and unpaid dividends, if any, on such shares of Series A Preferred Stock, divided by the conversion price of $2.50, subject to adjustments. The shares of Series A Preferred Stock are subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions or other similar events. Shares of capital stock of the Company shall be junior in rank to all shares of Series A Preferred Stock with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding-up of the Company. Each holder of shares of Series A Preferred Stock shall be entitled to receive dividends, which dividends shall be paid by the Company out of funds legally available therefor, payable, subject to the conditions and other terms hereof, in shares of common stock or cash on the stated value of such shares of Series A Preferred Stock at the dividend rate of two percent (2%) per annum, which shall be cumulative and shall continue to accrue and compound monthly whether or not declared. Holders of shares of Series A Preferred Stock, shall be entitled to vote on any proposals voted on by the common shareholders. Warrants to purchase 1,900,000 shares of the Company's common stock at an initial exercise price of $3.56 per share and expiring March 15, 2020, were also issued with the convertible note financing. The Company has evaluated the guidance ASC 480-10 Distinguishing Liabilities from Equity, A Contracts in an Entity's Own Equity Debt with Conversion and Other Options In connection with the private placements, the Company also entered into a registration rights agreement, with the investors pursuant to which the Company agreed to file a registration statement covering the resale of the shares of common stock issuable upon exercise or conversion of the securities and to maintain its effectiveness until all such securities have been sold or may be sold without restriction. In the event a registration statement covering such shares of common stock is not effective, the Company is required to pay to the investors on a monthly basis an amount equal to 1% of the investors' investment, not to exceed a total of 6%, subject to conditions as defined in the agreement. On April 20, 2017, the Company filed a registration statement with the Securities and Exchange Commission. As of the date of this filing, the registration statement is not yet effective. Restricted common stock award: During the nine months ended September 30, 2017, 422,000 restricted shares were granted to directors and officers, of which 40,000 were terminated upon the individuals’ separation from the Company. As of September 30, 2017, 42,622 restricted common shares had vested and been issued. See Note 7. Common stock escrow forfeiture: During the nine months ended September 30, 2017, under an agreement between the Company and one of the selling shareholders from the Company’s 2016 acquisition of BDI, rights to 32,801 common shares held in escrow on behalf of the selling shareholder were waived by the shareholder and returned to the Company where they were cancelled. Under the agreement each party mutually released each other from any and all claims that might relate to or arise from the acquisition of BDI. As a result of this cancellation, $134,812, which was the estimated fair market value of the 32,801 common shares, based upon $4.11 per share, was recorded as a gain in the BDI discontinued operations and a reduction in common stock. Equity rights terminations: During the nine months ended September 30, 2017, the Company negotiated and executed agreements with holders of stock rights (stock options and restricted shares) to have such holders waive their rights to the stock rights in exchange for a one time cash payment. The majority of the holders had previously terminated from the Company or the agreements were made as part of separation agreements upon the individuals’ termination from the Company. Under the agreements, a total of 532,911 rights were forfeited, consisting of; 494,578 stock options under the Company's 2002 Stock Incentive Plan (the “2002 Plan”), 37,500 non-qualified options issued outside of the 2002 Plan and 833 restricted common shares. The total consideration under the agreements was $299,500. For financial reporting purposes the amounts paid to each holder was compared to the fair value of the stock rights forfeited using a Black-Scholes valuation and to the extent the amount paid exceeded the value of the stock rights forfeited, the payment amount was charged to stock-based compensation. For purposes of the Black-Scholes valuation, the Company assumed a dividend yield of 0%, expected price volatility of 49% to 99% risk free interest rates of 0.8% to 2.3% and expected terms based upon the remaining lives of the instruments. Of the total amount paid, $291,995 was charged to stockholders’ equity and $7,505 was charged to compensation expense. Subsequent Stockholders’ Equity transactions: See Note 11 for stockholders’ equity transactions subsequent to September 30, 2017.

Stock based compensation, optio

Stock based compensation, options and warrants	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock based compensation, options and warrants	Note 7. Stock based compensation, options and warrants: Stock based compensation: The Company recognized total expenses for stock-based compensation during the three and nine months ended September 30, 2017 and 2016 which are included in the accompanying statements of operations, from the following categories: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Restricted stock awards under the Plan $ 100,396 $ — $ 188,572 $ — Stock option awards under the Plan 8,172 137,367 103,430 361,639 Non-qualified stock option awards — 6,820 87,620 6,820 Total stock-based compensation $ 108,568 $ 144,187 $ 379,622 $ 368,459 Restricted stock awards: A summary of the Company’s restricted stock activity in the nine months ended September 30, 2017 is presented here: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2017 - $ - Granted 422,000 3.69 Vested (42,622 ) 3.20 Forfeited (40,000 ) 3.13 Unvested at September 30, 2017 339,378 $ 3.75 During the nine months ended September 30, 2017, the Company granted 402,000 restricted shares to members of its Board of Directors and 20,000 restricted shares to an officer. Upon the separation of two Directors, 40,000 restricted shares were subsequently forfeited, including 833 restricted shares that were re-acquired by the Company as part of the equity rights terminations (see Note 6). The weighted-average grant date fair value of restricted shares granted during the nine months ended September 30, 2017 was $3.69 per share based upon the share price as of the date of grant. The total fair value of restricted stock granted, net of forfeitures, during the nine months ended September 30, 2017 was approximately $1,431,000, including approximately $136,000 which vested in the period. The value of restricted stock grants are measured based on their fair market value on the date of grant and amortized over their respective vesting periods, generally twenty-four months. As of September 30, 2017, there was approximately $1,248,000 of unrecognized compensation cost related to unvested restricted stock awards, which is expected to be recognized over a remaining weighted-average vesting period of approximately 1.6 years. Stock options: The Company currently provides stock-based compensation to employees, directors and consultants, both under the Company's 2017 Equity Incentive Plan (the "Plan"), and with non-qualified options and warrants issued outside of the Plan. During August 2017, the Company's shareholders approved the Plan including reservation of 895,000 shares of common stock under the Plan The Company's determination of the estimated fair value of share-based payment awards on the date of grant is affected by the following variables and assumptions: · Grant date exercise price – the closing market price of the Company's common stock on the date of the grant; · Estimated option term – based on historical experience with existing option holders; · Estimated dividend rates – based on historical and anticipated dividends over the life of the option; · Term of the option – based on historical experience, grants have lives of approximately 3-5 years; · Risk-free interest rates – with maturities that approximate the expected life of the options granted; · Calculated stock price volatility – calculated over the expected life of the options granted, which is calculated based on the daily closing price of the Company's common stock over a period equal to the expected term of the option; and · Option exercise behaviors – based on actual and projected employee stock option exercises and forfeitures. Stock incentive plan options: The Company currently provides stock-based compensation to employees, directors and consultants under the Plan. The Company utilized assumptions in the estimation of fair value of stock-based compensation for the nine months ended September 30, 2017 and 2016 as follows: 2017 2016 Dividend yield 0 % 0 % Expected price volatility 101 % 99-100 % Risk free interest rate 1.92 % 1.20 % Expected term 5 years 5 years A summary of activity under the Plan for the nine months ended September 30, 2017 is presented below: Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 2017 566,747 $ 20.46 Granted 20,000 4.02 Exercised (34,000 ) 2.89 Forfeited (495,414 ) 22.98 Outstanding at September 30, 2017 57,333 $ 3.32 9.1 $ 105,700 Exercisable at September 30, 2017 27,500 $ 3.07 8.8 $ 57,500 The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company's closing stock price on September 30, 2017 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders, had all option holders been able to, and in fact had, exercised their options on September 30, 2017. During the nine months ended September 30, 2017, 20,000 options were issued to a director under the Plan, exercisable at $4.02 per share with a grant date fair value of $3.04 per share. The options expire ten years from the date of grant and vest monthly in arrears, over a 24 month period. During the nine months ended September 30, 2017, 34,000 options outstanding under the Plan were exercised generating $98,260 in cash proceeds. The 34,000 options exercised had a total intrinsic value when exercised of $53,180. During the nine months ended September 30, 2016, no options were exercised. During the nine months ended September 30, 2016, 77,000 options were issued to non-employee directors under the Plan, exercisable at an average of $2.89 per share. The options expire ten years from the date of grant and vest 50% upon on the date of grant, and 25% on each of July 1, 2016 and October 1, 2016. During the nine months ended September 30, 2016, 150,000 options were issued to officers and employees under the Plan, exercisable at an average of $2.89 per share. The options expire ten years from the date of grant and vest 50% upon each of the nine month and the one year anniversary of the grant date. During the nine months ended September 30, 2017, a total of 495,414 options granted under the Plan were forfeited as part of the equity rights terminations (see Note 6). Of the total, 438,414 options were vested, exercisable at an average exercise price of $25.59 and 57,000 were unvested, exercisable at an average exercise price of $2.92. During the nine months ended September 30, 2016, a total of 25,445 options that were granted under the Plan were forfeited as a result of option holders’ terminations from the Company, of which 21,825 were vested and 3,620 were unvested. The vested options were exercisable at an average of $39.81 per share and the unvested options were exercisable at an average of $15.13 per share. The total fair value of stock options granted to employees and directors that vested and became exercisable during the nine months ended September 30, 2017 and 2016, was approximately $110,000 and $363,000, respectively. Based upon the Company’s experience, approximately 80% of the outstanding September 30, 2017 nonvested stock options, or approximately 24,000 options, are expected to vest in the future, under their terms. A summary of the activity of nonvested options under the Plan to acquire common shares granted to employees, officers, directors and consultants during the nine months ended September 30, 2017 is presented below: Nonvested Shares Nonvested Shares Underlying Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Nonvested at January 1, 2017 97,738 $ 3.51 $ 2.58 Granted 20,000 4.02 3.04 Vested (30,905 ) 4.92 3.57 Forfeited (57,000 ) 2.92 2.16 Nonvested at September 30, 2017 29,833 $ 3.54 $ 2.67 At September 30, 2017, based upon employee and director options granted under the Plan to that point, there was approximately $54,000 of additional unrecognized compensation cost related to stock options that will be recorded over a weighted average future period of approximately one year. Other common stock purchase options and warrants: As of September 30, 2017, in addition to the Plan options discussed above, the Company had outstanding 3,157,929 warrants in connection with offerings that were not issued under the Plan. In March 2017, the Company completed a total of $7.0 million in private placements of securities and in connection with those offerings, granted investors in the offerings, warrants which are classified as equity, exercisable six-months after issuance, to purchase a total of 2,800,000 shares of common stock, with 900,000 warrants at an exercise price of $3.50 per share and 1,900,000 warrants at an exercise price of $3.56 per share, all expiring in March 2020. See Note 6. During the nine month period ended September 30, 2016, 95,000 options were granted outside of the Plan. During the nine months ended September 30, 2017, these 95,000 options were forfeited. Operating expenses for the nine months ended September 30, 2017 and 2016, included $87,620 and $6,820, respectively, related to stock-based compensation. Following is a summary of outstanding options and warrants that were issued outside of the Plan for the nine months ended September 30, 2017: Shares Underlying Options / Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 2017 527,003 $ 13.36 Granted 2,800,000 3.54 Exercised - - Forfeited (169,074 ) 18.62 Outstanding at September 30, 2017 3,157,929 $ 4.37 2.3 $ 4,534,000 Exercisable at September 30, 2017 3,157,929 $ 4.37 2.3 $ 4,534,000 The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company's closing stock price on September 30, 2017 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders, had all option holders been able to, and in fact had, exercised their options on September 30, 2017. During the nine months ended September 30, 2017 and 2016, no warrants were exercised. At September 30, 2017 the 3,157,959 total outstanding warrants are non-compensatory rights, exercisable at an average of $4.37 per common share, expiring through March 2020, granted in connection with offerings. No rights are outstanding that have been granted under compensatory arrangements. During the nine months ended September 30, 2017, a total of 169,074 options and warrants that were granted outside of the Plan were forfeited. Of the total forfeited, 71,574 warrants expired under their terms and 60,000 options lapsed (15,000 vested and 45,000 unvested) due to the holders’ terminations from the Company. The 60,000 options which lapsed were exercisable at an average of $3.78 per share. The remaining 37,500, which were forfeited resulted from negotiated payments made to each holder to waive their rights to the outstanding options. See Note 6.

Animal Health License Agreement

Animal Health License Agreements	9 Months Ended
	Sep. 30, 2017
Animal Health License Agreements [Abstract]
Animal Health License Agreements	Note 8. Animal Health License Agreements: Effective May 1, 2004, Washington University in St. Louis ("WU") and the Company entered into an Exclusive License Agreement ("WU License Agreement"), which granted the Company exclusive license and right to sublicense WU's technology (as defined under the WU License Agreement) for veterinary products worldwide, except where such products are prohibited under U.S. laws for export. The term of the WU License Agreement continues until the expiration of the last of WU's patents (as defined in the WU License Agreement) expire. The Company agreed to pay minimum annual royalties of $20,000 during the term of the WU License Agreement and such amounts are creditable against future royalties. Royalties payable to WU under the WU License Agreement for covered product sales by the Company carry a mid-single digit royalty rate and for sublicense fees received by the Company carry a low double-digit royalty rate. The WU License Agreement contains customary terms for confidentiality, prosecution and infringement provisions for licensed patents, publication rights, indemnification and insurance coverage. The WU License Agreement is cancelable by the Company with ninety days advance notice at any time and by WU with sixty days advance notice if the Company materially breaches the WU License Agreement and fails to cure such breach. In July 2012, the Company entered into an Exclusive License Agreement (the "License Agreement") with Ceva Santé Animale S.A. ("Licensee"), pursuant to which the Company granted the Licensee an exclusive royalty-bearing license, until December 31, 2028, to the Company's intellectual property and other assets, including patent rights and know-how, relating to recombinant single chain reproductive hormone technology for use in non-human mammals (the "Company's Animal Health Assets"). The License Agreement is subject to termination by the Licensee (a) for convenience on 180 days prior written notice, (b) in the Licensee's discretion in the event of a sale or other disposal of the Company's animal health assets, (c) in the Licensee's discretion upon a change in control of the Company, (d) for a material breach of the License Agreement by the Company, or (e) in the Licensee's discretion, if the Company becomes insolvent. The License Agreement is also terminable by the Company if there is a material breach of the License Agreement by the Licensee, or if the Licensee challenges the Company's ownership of designated intellectual property. The License Agreement includes a sublicense of the technology licensed to the Company by WU. Under the terms of the WU License Agreement, a portion of license fees and royalties the Company receives from sublicensing agreements will be paid to WU. The obligation for such license fees due to WU is included in accrued expenses at September 30, 2017. Under the License Agreement, the Licensee obtained a worldwide exclusive license to develop, seek regulatory approval for and offer to sell, market, distribute, import and export luteinizing hormone ("LH") and/or follicle-stimulating hormone ("FSH") products for bovine (cattle), equine and swine in the field of the assistance and facilitation of reproduction in bovine, equine and swine animals. Under the License Agreement, as of September 30, 2017, the following future milestone payments are provided, assuming future milestones are successfully achieved: • milestone payments, totaling up to a potential of $1.1 million in the aggregate, based on the satisfactory conclusion of milestones as defined in the License Agreement; • potential for milestone payments of up to an additional $2 million for development and receipt of regulatory approval for additional licensed products; and • royalties, at low double digit rates, based on sales of licensed products. Revenue recognition related to the License Agreement and WU License Agreement is based primarily on the Company's consideration of ASC 808-10-45, " Accounting for Collaborative Arrangements. A tabular summary of the revenue categories and cumulative amounts of revenue recognition associated with the License Agreement follows: Category Totals License fees and milestone amounts paid / achieved $ 1,920,000 Third party obligations recorded, including WU (363,700 ) Deferred revenue balance 1,556,300 Revenue amortization to September 30, 2017 (466,810 ) Net deferred revenue balance at September 30, 2017 $ 1,089,490 Commencement of license fees revenue recognition Upon signing or receipt Commencement of milestone revenue recognition Upon milestone achievement over then remaining life Original amortization period 197 months

Acquisition and Discontinued Op

Acquisition and Discontinued Operations	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Acquisition and Discontinued Operations	Note 9. Acquisition and Discontinued Operations: Acquisition: On September 12, 2016, the Company completed the strategic acquisition of BDI, a privately-held entity. Pursuant to a purchase agreement (the "Purchase Agreement"), through a wholly-owned subsidiary ("Venaxis Sub"), the Company acquired all of the outstanding shares of Series 1 Preferred Stock of BDI from the selling shareholders (the "Seller"), representing more than 98% of the outstanding voting stock of BDI, and BDI thereupon become a majority owned subsidiary of the Company. Under the terms of the Purchase Agreement, the consideration consisted of an aggregate of 627,010 shares of the Company's common stock (the "Shares") which Shares were distributed in accordance with the liquidation preferences set forth in BDI's Fifth Amended and Restated Certificate of Incorporation, as amended. The Shares were valued at approximately $2,577,000 (based upon the closing value of our common stock on the acquisition date) and the issuance represented approximately 14% of the Company’s then outstanding common stock at the closing. The Purchase Agreement contained customary representations and warranties of the parties, including BDI, and the Sellers have customary indemnification obligations to the Company relating to BDI, which are subject to certain limitations described further in the Purchase Agreement. The issuance of the Shares was effected as a private placement of securities. The Company also entered into a registration rights agreement with the Sellers. The total consideration transferred consisted of the 627,010 shares of the Company's common stock with a value of $2,577,000. Under the acquisition method of accounting, the total estimated purchase consideration was allocated to the acquired tangible and intangible assets and assumed liabilities based on their estimated fair values as of the acquisition date. Following was the allocation of the purchase consideration: Cash and cash equivalents $ 17,000 Accounts receivable 21,000 Inventory 379,000 Prepaid and other assets 51,000 Equipment 1,000 Identifiable intangible assets: Trademarks (5 year estimated useful life) 99,000 Customer base (6 year estimated useful life) 37,000 Developed technology (4 year estimated useful life) 1,864,000 Total identifiable intangible assets 2,000,000 Goodwill 430,000 Accounts payable (118,000 ) Accrued and other liabilities (175,000 ) Non-controlling interest (29,000 ) Purchase price $ 2,577,000 Intangible assets acquired consisted of the following as of December 31, 2016: Trademarks $ 99,000 Customer base 37,000 Developed technology 1,864,000 Total 2,000,000 Less accumulated amortization (148,264 ) Balance at December 31, 2016 $ 1,851,736 As of November 30, 2016, the Company paid approximately $29,000 to acquire the non-controlling interest in BDI, which was accounted for as an equity transaction. The unaudited supplemental pro forma information for the nine months ended September 30, 2016, as if the BDI acquisition had occurred as of January 1, 2016, would have reflected total revenue of $174,000, net loss of $2,102,000 and loss per share of $0.47. These pro forma condensed consolidated financial results have been prepared for comparative purposes only and include certain adjustments to reflect the pro forma results of operations as if the acquisition had occurred as of the beginning of the periods presented, such as increased amortization for the fair value of acquired intangible assets. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities. As of December 31, 2016 inventories, included with current assets of discontinued operations, totaled approximately $416,000, consisting of $188,000 in raw materials and $228,000 in finished goods, all associated with the BDI operations. As of September 30, 2017 no inventories were on hand. Discontinued operations: During the quarter ended March 31, 2017, the Company made the decision to discontinue the operations of its wholly-owned subsidiary BDI. BDI had developed a proprietary Enhanced Surface Plasmon Resonance technology platform for the detection of molecular interactions. The decision to adopt this plan was made following an evaluation by the Company's Board of Directors in January 2017 of the estimated results of operations projected during the near to mid-term period for BDI, including consideration of product development required and updated sales forecasts, and estimated additional cash resources required. The Company expects to dispose of the assets and operations during 2017 by selling the assets and licensing the intellectual property rights. The Company has recognized the exit of BDI in accordance with Accounting Standards Codification (ASC) 205-20, Discontinued Operations The Company's historical financial statements have been revised to present the operating results of the BDI business as a discontinued operation. Assets and liabilities related to the discontinued operations of BDI are approximately as follows as of September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Current assets: Accounts receivable $ 8,000 $ 5,000 Inventories - 416,000 Prepaid expenses 4,000 66,000 Total current assets $ 12,000 $ 487,000 Equipment and furnishings, net $ - $ 36,000 Intangible assets, net - 2,281,000 Deposit - 37,000 Total noncurrent assets $ - $ 2,354,000 Current liabilities: Accounts payable $ 37,000 $ 174,000 Accrued expenses 28,000 85,000 Deferred revenue 137,000 - Total current liabilities $ 202,000 $ 259,000 Summarized results of the discontinued operation are as follows for the three and nine months ended September 30, 2017: Three Months Nine Months Sales $ 7,000 $ 37,000 Cost of sales 2,000 6,000 Gross margin 5,000 31,000 Operating expenses (credit) (26,000 ) 975,000 Operating income (loss) 31,000 (944,000 ) Escrow forfeiture gain - 135,000 Impairment (loss) - (2,754,000 ) Income (loss) from discontinued operations $ 31,000 $ (3,563,000 ) Included in the impairment loss recognized for the nine months ended September 30, 2017 on the discontinuance of BDI are impairment losses recognized on inventories of $453,000, equipment and furnishings of $29,000, identifiable intangible assets of $1,833,000, goodwill of $430,000, and a $9,000, net expense from all other items, all associated with the assets and operations of BDI. For the three and nine months ended September 30, 2016 the loss from discontinued operations of $236,000, consisted of revenues of $2,000, less operating and other expenses totaling $238,000, including amortization and depreciation of $24,000. Additional costs associated with the exit of operations of the Company's subsidiary BDI may be incurred as strategic options for BDI are evaluated.

Commitments and contingencies

Commitments and contingencies	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Note 10. Commitments and contingencies: Commitments: The Company's subsidiary, BDI, had a lease commitment on its office and laboratory space that was scheduled to expire March 31, 2018, requiring future non-cancellable lease payments as of May 2017 of approximately $294,000 for the remainder of its original term. During May 2017, an agreement with the subsidiary's landlord was reached to terminate the lease by surrendering the facility in May 2017, making a $80,419 prepayment of rent through July 31, 2017 and surrendering the $37,000 lease deposit. Rent expense for the nine months ended September 30, 2017 totaled approximately $229,000, including $216,000 in rent expense for BDI, inclusive of the payment of the early termination fee and the surrender of the $37,000 lease deposit and $13,000 in rent expense incurred by the Company under short-term rent agreements. The Company’s rent expense for the nine months ended September 30, 2016 was immaterial. On February 25, 2016, the Company completed the sale of its corporate headquarters, land, building and certain fixtures and equipment to a third party at a purchase price of $4,053,000. The sale resulted in a gain of approximately $1,933,000 and generated approximately $1,799,000 in net cash after expenses and mortgage payoffs. The Company is renting space in the building under short-term lease agreements that provide certain storage space. As of September 30, 2017, the Company has an employment agreement with one officer providing aggregate annual minimum commitments totaling approximately $272,000. The agreement contains customary confidentiality and benefit provisions. Contingencies: In the ordinary course of business and in the general industry in which the Company is engaged, it is not atypical to periodically receive a third party communication which may be in the form of a notice, threat, or "cease and desist" letter concerning certain activities. For example, this can occur in the context of the Company's pursuit of intellectual property rights. This can also occur in the context of operations such as the using, making, having made, selling, and offering to sell products and services, and in other contexts. The Company makes rational assessments of each situation on a case-by-case basis as such may arise. The Company periodically evaluates its options for trademark positions and considers a full spectrum of alternatives for trademark protection and product branding. We are currently not a party to any legal proceedings, the adverse outcome of which would, in our management's opinion, have a material adverse effect on our business, financial condition and results of operations.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 11. Subsequent Events: Corporate Name Change: On October 2, 2017 the Board of Directors of the Company approved a merger (the “Merger”) of the Company with its wholly-owned subsidiary, Riot Blockchain, Inc., a Nevada corporation (the “Merger Sub”), solely for the purpose of changing the name of the Company. Upon consummation of the Merger, the separate existence of Merger Sub ceased. As permitted by Chapter 92A.180 of Nevada Revised Statutes, the purpose of the Merger was to effect a change of the Company’s name to Riot Blockchain, Inc. from Bioptix, Inc. Upon approval by NASDAQ, on October 19, 2017, the Company’s name was thereupon changed. Cash Dividend: On October 2, 2017, the Company’s Board of Directors approved a cash dividend pursuant to which the holders of the Company’s common stock and Series A Preferred Stock, would receive $1.00 for each share of Common Stock held, including each share of Common Stock that would be issuable upon conversion of the Series A Preferred Stock, on an as converted basis. The cash dividend totaled approximately $9,562,000 with a record date of the close of business on October 13, 2017 and payment date of October 18, 2017. Temporary Reduction in Warrant Exercise Prices: On October 10, 2017, the Company’s Board of Directors approved a temporary reduction in the exercise price of warrants issued in the March 2017 private offerings to $3.00 per share. The approval covered any of the 2,800,000 outstanding warrants which would be exercised by their holders from October 10, 2017 through October 20, 2017, for cash. During that period 620,000 warrants were exercised for cash, as described below. Any such warrant holder who exercises such warrants for cash at the reduced price shall not be entitled to the benefit of any cashless exercise feature on such exercised warrants for cash. The fair value of the temporary modification of the exercise price will be recorded as an additional expense and a credit to capital in the fourth quarter of 2017. The fair value will be computed based upon the 620,000 warrants actually exercised times the increase in value of the warrants immediately before and immediately after the reduction in exercise price. Common Stock Transactions: Subsequent to September 30, 2017, the holders of 8,284.04 shares of Series A Preferred Stock exercised their right to convert such shares into 828,404 shares of common stock. Separately, the holders of 620,000 warrants issued in the March 2017 private offerings (420,000 from the common stock offering and 200,000 from the convertible note offering), exercised their warrants for cash during the temporary reduction in exercise price period, described above, and were issued 620,000 shares of common stock generating $1,860,000 in cash proceeds. Additionally, the holders of 2,060,000 warrants issued in the March 2017 private offerings (360,000 from the common stock offering, exercisable at $3.50 per share and 1,700,000 from the convertible note offering, exercisable at $3.56 per share), exercised their warrants on a cashless basis, as provided in the offering agreements and were issued 1,228,690 shares of common stock in exchange for surrender of their warrants. Tess Inc. Acquisition: On October 20, 2017, the Company acquired approximately 52% of TESS which is developing blockchain solutions for telecommunications companies. Under the terms of the Purchase Agreement (the “Purchase Agreement”) the Company invested cash of $320,000 and issued 75,000 shares of restricted Common Stock in exchange for 2,708,333 shares of common stock of TESS. Accordingly, TESS became a majority-owned subsidiary of the Company. In connection with the transaction, the Company and TESS entered into a registration rights agreement pursuant to which the Company agreed to file a registration statement within three months to register the resale of 25,000 shares (of 75,000 shares) of Common Stock issued to TESS. As of October 20, 2017 TESS has net tangible assets of approximately $10,000 and the Company expects that the purchase price will be allocated to intangible assets including in-process research and development and goodwill. Kairos Global Technology, Inc. Acquisition: On November 1, 2017, the Company entered into a business combination share exchange agreement (the “Agreement”) with Kairos Global Technology, Inc., a Nevada corporation and on November 3, 2017, closed on the agreement. Under the Agreement, the shareholders of Kairos agreed to exchange all outstanding shares of Kairos’ common stock to the Company and the Company agreed to issue an aggregate of One Million Seven Hundred Fifty Thousand and One (1,750,001) newly-designated shares of Series B Convertible Preferred Stock (the “Series B Preferred Stock”) which are convertible into an aggregate of One Million Seven Hundred Fifty Thousand and One (1,750,001) shares of the Company’s common stock, no par value per share (the transaction, the “Kairos Transaction”) to such shareholders. The shareholders of Kairos also will receive a royalty to be paid from cash flow generated from operations, which shall entitle such shareholders to receive 40% of the gross profits generated on a monthly basis until they have received a total of $1,000,000, at which point the royalty is extinguished. Karios is the owner of certain computer equipment and other assets used for the mining of cryptocurrency, specifically servers consisting of 700 AntMiner S9s and 500 AntMiner L3s, all manufactured by Bitmain. The shares of Series B Preferred Stock are convertible into shares of common stock based on a conversion calculation equal to the stated value of the Series B Preferred Stock, plus all accrued and unpaid dividends, if any, on such Series B Preferred Stock, as of such date of determination, divided by the conversion price. The stated value of each share of Series B Preferred Stock is $6.80 and the initial conversion price is $6.80 per share, each subject to adjustment for stock splits, stock dividends, recapitalizations, combinations, subdivisions or other similar events. The holders of Series B Preferred Stock are entitled to receive dividends if and when declared by the Company’s board of directors. The Series B Preferred Stock will participate on an “as converted” basis, with all dividends when and if declared, on the Company’s common stock. Each holder is entitled to vote on all matters submitted to stockholders of the Company, and will have the number of votes equal to the number of shares of common stock issuable upon conversion of such holder’s Series B Preferred Stock. Under the agreement the Company is prohibited from effecting a conversion of the Series B Preferred Stock to the extent that, as a result of such conversion, the holder would beneficially own more than 4.99% percent of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon conversion of the Series B Preferred Stock, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99% percent. The Series B Preferred Stock contains a blocker pursuant to which, if the Company has not obtained the approval of its shareholders in accordance with NASDAQ Listing Rule 5635(d), then the Company may not issue upon conversion of the Series B Preferred Stock a number of shares of common stock, which, when aggregated with any other shares of common stock underlying the Series B Preferred Stock issued pursuant to the Agreement would exceed 19.99% of the shares of common stock issued and outstanding as of the date of the Agreement, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the common stock that occur after the date of the Agreement.

Significant accounting polici20

Significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation The consolidated financial statements of the Company include the accounts of Riot Blockchain and its wholly-owned subsidiary, BDI. Intercompany accounts and transactions have been eliminated in the consolidation.
Investment in affiliate	Investment in affiliate The Company’s 10.9% investment in Coinsquare is accounted for on the cost method.
Cash, cash equivalents and short-term investments	Cash, cash equivalents and short-term investments: The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. From time to time, the Company's cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. The Company invests excess cash from time to time in highly-liquid debt and equity investments of highly-rated entities, which are classified as trading securities. Such amounts are recorded at market values using Level 1 inputs in determining fair value and are generally classified as current, as the Company does not intend to hold the investments beyond twelve months. Investment securities classified as trading are those securities that are bought and held principally for the purpose of selling them in the near term, with the objective of preserving principal and generating profits. These securities are reported at fair value with unrealized gains and losses reported as an element of other (expense) income in current period earnings. The Company's Board of Directors has approved an investment policy covering the investment parameters to be followed with the primary goals being the safety of principal amounts and maintaining liquidity. The policy provides for minimum investment rating requirements as well as limitations on investment duration and concentrations. Based upon market conditions, the investment guidelines have been tightened to increase the minimum acceptable investment ratings required for investments and shorten the maximum investment term. As of September 30, 2017, 100% of the investment portfolio was in cash and cash equivalents, which is presented as such on the accompanying balance sheet. The Company's short-term investments comprise certificates of deposit, commercial paper and corporate bonds, all of which are classified as trading securities and carried at their fair value based upon quoted market prices of the securities at December 31, 2016. Net realized and unrealized gains and losses on trading securities are included in net loss. For purposes of determining realized gains and losses, the cost of securities sold is based on specific identification. The composition of trading securities is as follows at December 31, 2016: December 31, 2016 Cost Fair Value Certificates of deposit / commercial paper $ 2,378,222 $ 2,373,891 Corporate bonds 5,138,182 5,132,870 Total trading securities $ 7,516,404 $ 7,506,761 Investment income for the nine months ended September 30, 2017 and 2016 consists of the following: 2017 2016 Interest income $ 84,177 $ 101,236 Realized (losses) (21 ) (2,893 ) Unrealized gains 11,575 21,501 Management fee expenses (12,484 ) (16,813 ) Net investment income $ 83,247 $ 103,031
Fair value of financial instruments	Fair value of financial instruments: The Company accounts for financial instruments under Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic ("ASC") 820, Fair Value Measurements Level 1— quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 — observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 — assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company's market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. There were no financial assets or liabilities measured at fair value, with the exception of short-term investments as of December 31, 2016. The carrying amounts of the Company's financial instruments (other than short-term investments as discussed above) approximate fair value because of their variable interest rates and/or short maturities combined with the recent historical interest rate levels.
Revenue Recognition	Revenue Recognition: Revenue recognition related to the license agreement is based upon the licensee's right to use the technology and the Company's ongoing obligations to maintain and defend the patented rights and comply with the terms of the sub-license agreement whereby the license fees and milestone payments received from the agreement, net of the amounts due to third parties, have been recorded as deferred revenue and are amortized over the term of the license agreement.
Goodwill	Goodwill: The Company performs a goodwill impairment analysis in the fourth quarter of each year, or whenever there is an indication of impairment. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation to determine if it is more likely than not that the fair value of its reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a two-step goodwill impairment test. The Company has determined, based on its evaluation, that the goodwill associated with the BDI acquisition was impaired and was written off during the nine months ended September 30, 2017, included as part of the discontinued operations impairment loss.
Recently issued and adopted accounting pronouncements	Recently issued and adopted accounting pronouncements: The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company's financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company's consolidated financial statements properly reflect the change. In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update No. 2014-09, Revenue from Contracts with Customers In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows In January 2017, the FASB issued an ASU 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) In May 2017, the FASB issued ASU No. 2017-09, "Compensation-Stock Compensation: Scope of modification accounting". ASU 2017-09 provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU No. 2017-09 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted, including during an interim period for which financial statements have not yet been made available for issuance. The amendments should be applied prospectively to an award modified on or after the adoption date. The Company is currently evaluating the impact that the adoption of ASU 2017-09 will have on its consolidated financial statements. In July 2017, the FASB issued ASU No. 2017-11, "Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815)," which addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.
Income (loss) per share	Income (loss) per share: ASC 260, Earnings Per Share Basic net income (loss) per share includes no dilution and is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding for the period, excluding any nonvested restricted common shares. Diluted net income (loss) per share reflect the potential dilution of securities that could share in the Company's income (loss). The effect of the inclusion of the dilutive shares would have resulted in a decrease in loss per share for the periods ended September 30, 2017 and 2016. Outstanding stock options, warrants and other dilutive rights are not considered in the calculation, as the impact of the potential common shares (totaling approximately 5,474,000 shares and 1,061,000 shares for each of the nine month periods ended September 30, 2017 and 2016, respectively) would be anti-dilutive. For the nine months ended September 30, 2017 the dilutive rights not considered in the calculation, include shares of Series A Convertible Preferred Stock (“Series A Preferred Stock”) outstanding that are convertible into 1,919,472 common shares. For periods when shares of preferred stock are outstanding, the two-class method is used to calculate basic and diluted earnings (loss) per common share since such preferred stock is a participating security under ASC 260 Earnings per Share. Under the provisions of ASC 260, "Earnings Per Share," basic EPS shall be computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Income available to common stockholders shall be computed by deducting both the dividends declared in the period on preferred stock and the dividends accumulated for the period on cumulative preferred stock from income from continuing operations. Dividends during the nine months ended September 30, 2017 were de minimis

Significant accounting polici21

Significant accounting policies (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Schedule of Trading Securities	The composition of trading securities is as follows at December 31, 2016: December 31, 2016 Cost Fair Value Certificates of deposit / commercial paper $ 2,378,222 $ 2,373,891 Corporate bonds 5,138,182 5,132,870 Total trading securities $ 7,516,404 $ 7,506,761
Schedule of Investment Income	Investment income for the nine months ended September 30, 2017 and 2016 consists of the following: 2017 2016 Interest income $ 84,177 $ 101,236 Realized (losses) (21 ) (2,893 ) Unrealized gains 11,575 21,501 Management fee expenses (12,484 ) (16,813 ) Net investment income $ 83,247 $ 103,031

Property and equipment (Tables)

Property and equipment (Tables)	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following: September 30, 2017 December 31, 2016 Office and computer equipment $ 114,309 $ 116,510 Less accumulated depreciation 110,196 110,972 $ 4,113 $ 5,538

Other long-term assets (Tables)

Other long-term assets (Tables)	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Other Long-Term Assets	Other long-term assets consisted of the following as of September 30, 2017 and December 31, 2016: Beginning Balance (December 31, 2016) Additions Impairments Ending Balance (September 30, 2017) Cost: Patents $ 1,032,982 $ 14,255 $ — $ 1,047,237 Goodwill 447,951 — — 447,951 Total 1,480,933 14,255 — 1,495,188 Accumulated Amortization: Patents (482,183 ) (52,974 ) — (535,157 ) Goodwill (60,712 ) — — (60,712 ) Total (542,895 ) (52,974 ) — (595,869 ) Net Other Long Term Assets $ 938,038 $ (38,719 ) $ — $ 899,319

Stock options and warrants (Tab

Stock options and warrants (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Recognized Stock-based Compensation	The Company recognized total expenses for stock-based compensation during the three and nine months ended September 30, 2017 and 2016 which are included in the accompanying statements of operations, from the following categories: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Restricted stock awards under the Plan $ 100,396 $ — $ 188,572 $ — Stock option awards under the Plan 8,172 137,367 103,430 361,639 Non-qualified stock option awards — 6,820 87,620 6,820 Total stock-based compensation $ 108,568 $ 144,187 $ 379,622 $ 368,459
Summary of Stock Restricted Plan Activity	A summary of the Company’s restricted stock activity in the nine months ended September 30, 2017 is presented here: Number of Shares Weighted Average Grant-Date Fair Value Unvested at January 1, 2017 - $ - Granted 422,000 3.69 Vested (42,622 ) 3.20 Forfeited (40,000 ) 3.13 Unvested at September 30, 2017 339,378 $ 3.75
Schedule of Fair Value Assumptions Used to Estimate Stock-based Compensation	The Company utilized assumptions in the estimation of fair value of stock-based compensation for the nine months ended September 30, 2017 and 2016 as follows: 2017 2016 Dividend yield 0 % 0 % Expected price volatility 101 % 99-100 % Risk free interest rate 1.92 % 1.20 % Expected term 5 years 5 years
Summary of Stock Incentive Plan Activity	A summary of activity under the Plan for the nine months ended September 30, 2017 is presented below: Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 2017 566,747 $ 20.46 Granted 20,000 4.02 Exercised (34,000 ) 2.89 Forfeited (495,414 ) 22.98 Outstanding at September 30, 2017 57,333 $ 3.32 9.1 $ 105,700 Exercisable at September 30, 2017 27,500 $ 3.07 8.8 $ 57,500
Schedule of Nonvested Share Activity	A summary of the activity of nonvested options under the Plan to acquire common shares granted to employees, officers, directors and consultants during the nine months ended September 30, 2017 is presented below: Nonvested Shares Nonvested Shares Underlying Options Weighted Average Exercise Price Weighted Average Grant Date Fair Value Nonvested at January 1, 2017 97,738 $ 3.51 $ 2.58 Granted 20,000 4.02 3.04 Vested (30,905 ) 4.92 3.57 Forfeited (57,000 ) 2.92 2.16 Nonvested at September 30, 2017 29,833 $ 3.54 $ 2.67
Schedule of Nonqualified Award Activity	Following is a summary of outstanding options and warrants that were issued outside of the Plan for the nine months ended September 30, 2017: Shares Underlying Options / Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 2017 527,003 $ 13.36 Granted 2,800,000 3.54 Exercised - - Forfeited (169,074 ) 18.62 Outstanding at September 30, 2017 3,157,929 $ 4.37 2.3 $ 4,534,000 Exercisable at September 30, 2017 3,157,929 $ 4.37 2.3 $ 4,534,000

Animal Health License Agreeme25

Animal Health License Agreements (Tables)	9 Months Ended
	Sep. 30, 2017
Animal Health License Agreements [Abstract]
Schedule of Current and Long-Term Deferred Revenues	A tabular summary of the revenue categories and cumulative amounts of revenue recognition associated with the License Agreement follows: Category Totals License fees and milestone amounts paid / achieved $ 1,920,000 Third party obligations recorded, including WU (363,700 ) Deferred revenue balance 1,556,300 Revenue amortization to September 30, 2017 (466,810 ) Net deferred revenue balance at September 30, 2017 $ 1,089,490 Commencement of license fees revenue recognition Upon signing or receipt Commencement of milestone revenue recognition Upon milestone achievement over then remaining life Original amortization period 197 months

Acquisition and Discontinued 26

Acquisition and Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Schedule of Assets and Liabilities Acquired	Under the acquisition method of accounting, the total estimated purchase consideration was allocated to the acquired tangible and intangible assets and assumed liabilities based on their estimated fair values as of the acquisition date. Following was the allocation of the purchase consideration: Cash and cash equivalents $ 17,000 Accounts receivable 21,000 Inventory 379,000 Prepaid and other assets 51,000 Equipment 1,000 Identifiable intangible assets: Trademarks (5 year estimated useful life) 99,000 Customer base (6 year estimated useful life) 37,000 Developed technology (4 year estimated useful life) 1,864,000 Total identifiable intangible assets 2,000,000 Goodwill 430,000 Accounts payable (118,000 ) Accrued and other liabilities (175,000 ) Non-controlling interest (29,000 ) Purchase price $ 2,577,000
Schedule of Intangible rights acquired	Intangible assets acquired consisted of the following as of December 31, 2016: Trademarks $ 99,000 Customer base 37,000 Developed technology 1,864,000 Total 2,000,000 Less accumulated amortization (148,264 ) Balance at December 31, 2016 $ 1,851,736
Schedule of Operation and Assets and Liabilities Related to Discontinued Operations	The Company's historical financial statements have been revised to present the operating results of the BDI business as a discontinued operation. Assets and liabilities related to the discontinued operations of BDI are approximately as follows as of September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Current assets: Accounts receivable $ 8,000 $ 5,000 Inventories - 416,000 Prepaid expenses 4,000 66,000 Total current assets $ 12,000 $ 487,000 Equipment and furnishings, net $ - $ 36,000 Intangible assets, net - 2,281,000 Deposit - 37,000 Total noncurrent assets $ - $ 2,354,000 Current liabilities: Accounts payable $ 37,000 $ 174,000 Accrued expenses 28,000 85,000 Deferred revenue 137,000 - Total current liabilities $ 202,000 $ 259,000 Summarized results of the discontinued operation are as follows for the three and nine months ended September 30, 2017: Three Months Nine Months Sales $ 7,000 $ 37,000 Cost of sales 2,000 6,000 Gross margin 5,000 31,000 Operating expenses (credit) (26,000 ) 975,000 Operating income (loss) 31,000 (944,000 ) Escrow forfeiture gain - 135,000 Impairment (loss) - (2,754,000 ) Income (loss) from discontinued operations $ 31,000 $ (3,563,000 )

INTERIM FINANCIAL STATEMENTS (D

INTERIM FINANCIAL STATEMENTS (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 13,139,722	$ 5,529,848	$ 2,447,320	$ 2,012,283
Working capital	12,555,000
Stockholders' equity	15,465,994	14,920,359
Accumulated deficit	$ 120,822,896	$ 109,855,276

Significant Accounting Polici28

Significant Accounting Policies (Income (Loss) Per Share) (Details) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares not included in the computation of EPS	5,474,000	1,061,000
Series A Preferred Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares not included in the computation of EPS	1,919,472

Significant Accounting Polici29

Significant Accounting Policies - (Schedule of Trading Securities) (Details)	Dec. 31, 2016USD ($)
Schedule of Trading Securities and Other Trading Assets [Line Items]
Trading securities cost, current	$ 7,516,404
Trading securities fair value, current	7,506,761
Certificates of deposit / commercial paper [Member]
Schedule of Trading Securities and Other Trading Assets [Line Items]
Trading securities cost, current	2,378,222
Trading securities fair value, current	2,373,891
Corporate Bonds [Member]
Schedule of Trading Securities and Other Trading Assets [Line Items]
Trading securities cost, current	5,138,182
Trading securities fair value, current	$ 5,132,870

Significant Accounting Polici30

Significant Accounting Policies (Schedule of Investment Income) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Interest income	$ 84,177	$ 101,236
Realized (losses)	(21)	(2,893)
Unrealized gains	11,575	21,501
Management fee expenses	(12,484)	(16,813)
Net investment income	$ 83,247	$ 103,031

Investment in Coinsquare (Detai

Investment in Coinsquare (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Minority interest	$ 3,000,000
Coinsquare [Member] | Warrant [Member]
Percentage of minority interest	14.70%
Maturity date	May 30, 2018
Coinsquare [Member]
Minority interest	$ 3,000,000
Percentage of minority interest	10.90%

Property and equipment (Narrati

Property and equipment (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Feb. 25, 2016
Property, Plant and Equipment [Abstract]
Sales price of corporate headquarters, land and building to a third party					$ 4,053,000
Gain on sale of property and equipment		$ 13,062		$ 1,933,335
Proceeds from sale of property and equipment				1,799,143
Depreciation expense	$ 500	$ 800	1,400	2,700
Depreciation and amortization expense relating to short-term assets included with prepaid expenses			$ 1,500	$ 12,000

Property and equipment (Schedul

Property and equipment (Schedule of Property and Equipment) (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Office and computer equipment	$ 114,309	$ 116,510
Less accumulated depreciation	110,196	110,972
Total property and equipment, net	$ 4,113	$ 5,538

Other long-term assets (Narrati

Other long-term assets (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Future amortization
2,018	$ 71,000		$ 71,000
2,019	71,000		71,000
2,020	71,000		71,000
2,021	71,000		71,000
2,022	71,000		71,000
Patent impairment charges		$ 32,000		$ 200,000

Other long-term assets (Schedul

Other long-term assets (Schedule of Other Long-Term Assets) (Details)	9 Months Ended
	Sep. 30, 2017USD ($)
Goodwill:
Goodwill, beginning	$ 447,951
Additions
Impairments
Goodwill, ending	447,951
Accumulated amortization	(60,712)
Total other long-term assets:
Cost, beginning	1,480,933
Additions	14,255
Impairments
Cost, ending	1,495,188
Cost, beginning	(542,895)
Additions	(52,974)
Impairments
Cost, ending	(595,869)
Other long-term assets, net, beginning	938,038
Additions	(38,719)
Impairments
Other long-term assets, net, ending	899,319
Patents [Member]
Patents:
Cost, beginning	1,032,982
Additions	14,255
Impairments
Cost, ending	1,047,237
Accumulated amortization, beginning	(482,183)
Additions	(52,974)
Impairments
Accumulated amortization, ending	$ (535,157)

Notes and Other Obligations (Na

Notes and Other Obligations (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Notes Payable	$ 215,712		$ 215,712		$ 139,611
Fixed interest rate	4.50%		4.50%
Interest expense	$ 4,773,397	$ 2,384	$ 4,802,296	$ 28,130
Mortgage Notes [Member]
Debt Instrument [Line Items]
Amortization period			15 years
Balloon maturity period			5 years
Mortgage Notes [Member] | Commercial Banks [Member]
Debt Instrument [Line Items]
Fixed interest rate	3.95%		3.95%
Mortgage Notes [Member] | U.S. Small Business Administration [Member]
Debt Instrument [Line Items]
Fixed interest rate	5.86%		5.86%
Private Placement [Member] | Warrant [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock	1,900,000		1,900,000
Exercise price	$ 3.56		$ 3.56
Maturity date			Mar. 15, 2020
Private Placement [Member] | Convertible Note [Member]
Debt Instrument [Line Items]
Fixed interest rate	2.00%		2.00%
Conversion price	$ 2.50		$ 2.50
Proceeds from convertible debt held in escrow			$ 4,750,000
Interest expense			$ 48,671
Issuance date			Mar. 16, 2017
Maturity date			Sep. 16, 2018

Stockholders' equity (Details)

Stockholders' equity (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Aug. 21, 2017	Aug. 20, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Proceeds from issuance of common stock				$ 1,913,509
Discount on Convertible Debt arising from values of beneficial conversion feature				2,424,849
Discount on Convertible Debt arising from values of warrants				$ 2,325,151
Common stock, shares authorized		170,000,000		170,000,000		170,000,000	60,000,000	60,000,000
Preferred stock, shares authorized		15,000,000		15,000,000				0
Conversion of notes payable and accrued interest to preferred stock				$ 4,798,671
Interest rate percentage		4.50%		4.50%
Interest expense		$ 4,773,397	$ 2,384	$ 4,802,296	$ 28,130
Rights forfeited				532,911
Total consideration under the agreements forfeited during period				$ 299,500
Total consideration under the agreements forfeited during period charged to equity				291,995
Total consideration under the agreements forfeited during period recorded as compensation				$ 7,505
Dividend yield				0.00%	0.00%
Expected term				5 years	5 years
Expected price volatility				101.00%
Risk free interest rate				1.92%	1.20%
Expected price volatility, minimum				49.00%
Expected price volatility, maximum				99.00%
Risk free interest rates, minimum				0.80%
Risk free interest rates, maximum				2.30%
2002 Stock Incentive Plan [Member]
Class of Stock [Line Items]
Rights forfeited				494,578
BDI [Member]
Class of Stock [Line Items]
Number of common shares previously held in escrow, cancelled during period				32,801
Estimated value of common shares recoded resulting in a reduction in impairment loss				$ 134,812
Share price		$ 4.11		$ 4.11
Restricted Stock [Member]
Class of Stock [Line Items]
Common shares vested				42,622
Rights forfeited				833
Restricted Stock [Member] | Directors and Officers [Member]
Class of Stock [Line Items]
Award of restricted shares				422,000
Shares terminated				40,000
Common shares vested				42,622
Non-qualified stock option awards [Member]
Class of Stock [Line Items]
Rights forfeited				37,500
Common Stock [Member]
Class of Stock [Line Items]
Discount on Convertible Debt arising from values of beneficial conversion feature				$ 2,424,849
Discount on Convertible Debt arising from values of warrants				$ 2,325,151
Preferred Stock issued upon Notes payable conversion, shares
Private Placement [Member]
Class of Stock [Line Items]
Total amount of financing from common stock units		$ 2,250,000		$ 2,250,000
Proceeds from issuance of common stock				$ 1,000,000
Issuance of common stock				400,000
Offering expenses incurred from private placement stock issuance				$ 336,491
Common stock shares held in escrow		500,000		500,000
Proceeds from common stock and warrants released				$ 1,250,000
Purchase price		$ 2.50		$ 2.50
Private Placement [Member] | Convertible Note [Member]
Class of Stock [Line Items]
Debt instrument face amount		$ 4,750,000		$ 4,750,000
Conversion price		$ 2.50		$ 2.50
Conversion of note principal balance				$ 4,750,000
Conversion of accrued interest on note				48,671
Conversion of notes payable and accrued interest to preferred stock				$ 4,798,671
Interest rate percentage		2.00%		2.00%
Interest expense				$ 48,671
Interest expense recognized on conversion of convertible notes				$ 4,750,000
Maturity date				Sep. 16, 2018
Private Placement [Member] | Warrant [Member]
Class of Stock [Line Items]
Number of warrants issued				900,000
Exercise price		$ 3.56		$ 3.56
Warrants to purchase common stock		1,900,000		1,900,000
Warrant to purchase term				3 years
Fair value of warrants	$ 2,114,000
Dividend yield	0.00%			0.00%
Expected term	3 years			3 years
Expected price volatility	114.00%			108.00%
Risk free interest rate	1.66%			1.47%
Maturity date				Mar. 15, 2020
Private Placement [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of common stock				900,000
Purchase price		$ 3.50		$ 3.50
Designated as 2% Series A Convertible Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		2,000,000		2,000,000
Series A Preferred Stock | Private Placement [Member]
Class of Stock [Line Items]
Preferred Stock issued upon Notes payable conversion, shares				19,195
Preferred stock stated value per share		$ 250		$ 250
Number of common share preferred holders have rights to		1,919,472		1,919,472

Stock based compensation, opt38

Stock based compensation, options and warrants (Stock Incentive Plan Options) (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved under the Plan	895,000
Fair value of options vested	$ 136,000
Net proceeds from exercise of stock options	$ 98,260
Rights forfeited	532,911
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	3 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	5 years
Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	20,000
Options granted, exercise price	$ 4.02
Options grant date fair value	$ 3.04
Options forfeited	495,414	25,445
Options forfeited, unvested	57,000
Options forfeited, exercise price	$ 22.98
Options forfeited, unvested, exercise price	$ 2.92
Fair value of options vested	$ 110,000	$ 363,000
Net proceeds from exercise of stock options	98,260
Total intrinsic value when exercised	$ 53,180
Expected to vest	24,000
Unrecognized compensation cost	$ 54,000
Unrecognized compensation cost, period for recognition	1 year
Director [Member] | Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	20,000
Options granted, exercise price	$ 4.02
Options grant date fair value	$ 3.04
Expiration period	10 years
Vesting period	24 months
Independent Directors [Member] | Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted		77,000
Options granted, exercise price		$ 2.89
Expiration period		10 years
Independent Directors [Member] | Stock Incentive Plan [Member] | Vesting in Period One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting rate		50.00%
Independent Directors [Member] | Stock Incentive Plan [Member] | Vesting in Period Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting rate		25.00%
Independent Directors [Member] | Stock Incentive Plan [Member] | Vesting in Period Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting rate		25.00%
Officers and Employees [Member] | Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted		150,000
Options granted, exercise price		$ 2.89
Expiration period		10 years
Officers and Employees [Member] | Stock Incentive Plan [Member] | Vesting in Period One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting rate		50.00%
Officers and Employees [Member] | Stock Incentive Plan [Member] | Vesting in Period Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting rate		50.00%
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	422,000
Options grant date fair value	$ 3.69
Options forfeited, unvested	40,000
Fair value of options vested	$ 1,431,000
Unrecognized compensation cost	$ 1,248,000
Unrecognized compensation cost, period for recognition	1 year 7 months 6 days
Rights forfeited	833
Restricted Stock [Member] | Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	402,000
Options forfeited	40,000
Restricted Stock [Member] | Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	20,000
Vested Options [Member] | Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options forfeited	438,414	21,825
Options forfeited, exercise price	$ 25.59	$ 39.81
Unvested Options [Member] | Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options forfeited	57,000	3,620
Options forfeited, unvested, exercise price	$ 2.92	$ 15.13

Stock based compensation, opt39

Stock based compensation, options and warrants (Other Common Stock Purchase Options and Warrants) (Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, operating expense		$ 108,568	$ 144,187	$ 379,622	$ 368,459
Proceeds from issuance of common stock				1,913,509
Private Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock				$ 1,000,000
Expiration date	May 31, 2020
Nonqualified [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards outstanding		3,157,929		3,157,929		527,003
Options granted	2,800,000			2,800,000
Options granted, exercise price	$ 3.50			$ 3.54
Options forfeited				169,074
Lapsed shares				60,000
Number of lapsed options vested				15,000
Number of lapsed options unvested				45,000
Unvested exercise price		$ 0		$ 0
Expired options				71,574
Remaining forfeited options				37,500
Nonqualified [Member] | Non Compensatory Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price		$ 4.37		$ 4.37
Awards outstanding		3,157,959		3,157,959
Expiration date				Mar. 31, 2020
Nonqualified [Member] | Compensatory Arrangements [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price		$ 3.78		$ 3.78
Expiration date				Jul. 31, 2017
Nonqualified [Member] | Warrants Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	900,000
Options granted, exercise price	$ 3.50
Nonqualified [Member] | Warrants Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	1,900,000
Options granted, exercise price	$ 3.56
Nonqualified [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted					95,000
Share-based compensation, operating expense				$ 87,620	$ 6,820
Options forfeited				95,000

Stock based compensation, opt40

Stock based compensation, options and warrants (Schedule of Stock-based Compensation) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 108,568	$ 144,187	$ 379,622	$ 368,459
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	100,396		188,572
Stock options awards under the Plan Member [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	8,172	137,367	103,430	361,639
Non-qualified stock option awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation		$ 6,820	$ 87,620	$ 6,820

Stock based compensation, opt41

Stock based compensation, options and warrants (Schedule of Restricted Stock Activity) (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Number of shares
Beginning balance | shares
Granted | shares	422,000
Vested | shares	(42,622)
Forfeited | shares	(40,000)
Ending balance | shares	339,378
Weighted Average Grant Date Fair value
Beginning balance | $ / shares
Granted | $ / shares	3.69
Vested | $ / shares	3.20
Forfeited | $ / shares	3.13
Ending balance | $ / shares	$ 3.75

Stock based compensation, opt42

Stock based compensation, options and warrants (Schedule of Assumptions in Estimation of Stock-Based Compensation) (Details)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Expected price volatility	101.00%
Risk free interest rate	1.92%	1.20%
Expected term	5 years	5 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected price volatility		99.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected price volatility		100.00%

Stock based compensation, opt43

Stock based compensation, options and warrants (Schedule of Award Activity) (Details) - USD ($)	1 Months Ended	9 Months Ended
	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016
Shares Underlying Options
Exercised		(34,000)
Nonqualified [Member]
Shares Underlying Options
Outstanding, beginning		527,003
Granted	2,800,000	2,800,000
Exercised
Forfeited		(169,074)
Outstanding, ending		3,157,929
Exercisable		3,157,929
Weighted Average Exercise Price
Outstanding, beginning		$ 13.36
Granted	$ 3.50	3.54
Exercised
Forfeited		18.62
Outstanding, ending		4.37
Exercisable		$ 4.37
Weighted Average Remaining Contractual Term
Outstanding		2 years 3 months 19 days
Exercisable		2 years 3 months 19 days
Aggregate Intrinsic Value
Outstanding		$ 4,534,000
Exercisable		$ 4,534,000
Stock Incentive Plan [Member]
Shares Underlying Options
Outstanding, beginning		566,747
Granted		20,000
Exercised		(34,000)
Forfeited		(495,414)	(25,445)
Outstanding, ending		57,333
Exercisable		27,500
Weighted Average Exercise Price
Outstanding, beginning		$ 20.46
Granted		4.02
Exercised		2.89
Forfeited		22.98
Outstanding, ending		3.32
Exercisable		$ 3.07
Weighted Average Remaining Contractual Term
Outstanding		9 years 1 month 6 days
Exercisable		8 years 9 months 18 days
Aggregate Intrinsic Value
Outstanding		$ 105,700
Exercisable		$ 57,500

Stock based compensation, opt44

Stock based compensation, options and warrants (Schedule of Nonvested Awards) (Details) - Stock Incentive Plan [Member]	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Nonvested Shares Underlying Options
Beginning balance | shares	97,738
Granted | shares	20,000
Vested | shares	(30,905)
Forfeited | shares	(57,000)
Ending balance | shares	29,833
Weighted Average Exercise Price
Beginning balance	$ 3.51
Granted	4.02
Vested	4.92
Forfeited	2.92
Ending balance	3.54
Weighted Average Grant Date Fair Value
Beginning balance	2.58
Granted	3.04
Vested	3.57
Forfeited	2.16
Ending balance	$ 2.67

Animal Health License Agreeme45

Animal Health License Agreements (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Animal Health License Agreements [Abstract]
Annual royalty commitment	$ 20,000
Prior written notice period for termination of license agreement by the licensee	180 days
Aggregate milestone payments, maximum	$ 1,100,000
Additional milestone payments, maximum	2,000,000
Original amount of deferred revenue	1,556,300
Deferred revenue	96,698		$ 96,698
Deferred revenue, noncurrent	992,792		$ 1,065,316
Recognition of license fee revenue	$ 72,524	$ 72,524

Animal Health License Agreeme46

Animal Health License Agreements (Schedule of Revenue Recognition Associated with the License Agreement) (Details)	9 Months Ended
	Sep. 30, 2017USD ($)
Animal Health License Agreements [Abstract]
License fees and milestone amounts paid / achieved	$ 1,920,000
Third party obligations recorded, including WU	(363,700)
Deferred revenue balance	1,556,300
Revenue amortization to September 30, 2017	(466,810)
Net deferred revenue balance at September 30, 2017	$ 1,089,490
Original amortization period	197 months

Acquisition and Discontinued 47

Acquisition and Discontinued Operations (Narrative) (Details) - USD ($)	Sep. 12, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
Impairment loss on Goodwill
Total income (loss) from discontinued operations		$ 30,922	$ (236,473)	(3,563,876)	$ (236,473)
BDI [Member]
Business Acquisition [Line Items]
Percentage of outstanding voting stock owned by parent	98.00%
Percentage of Venaxis common stock issued as equity consideration	14.00%
Inventories acquired						$ 416,000
Inventories raw materials acquired						188,000
Inventories finished goods acquired						$ 228,000
Total revenue					174,000
Net loss					$ 2,102,000
Loss per share (Basic and Diluted)					$ 0.47
Impairment loss on Inventory				453,000
Impairment loss on Goodwill				430,000
Impairment loss of Equipment and furnishings				29,000
Impairment loss of Intangible Assests				1,833,000
Impairment loss on other items				9,000
Sales		$ 7,000	2,000	$ 37,000	$ 2,000
Operating and other expenses			238,000		238,000
Depreciation and amortization			$ 24,000		$ 24,000
BDI [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Equity consideration issued for acquisition, number of shares	627,010
Value of equity consideration issued for acquisition	$ 2,577,000

Acquisition and Discontinued 48

Acquisition and Discontinued Operations (Schedule of Assets and Liabilities Acquired) (Details) - USD ($)	1 Months Ended	9 Months Ended
	Nov. 30, 2016	Sep. 30, 2017	Dec. 31, 2016
Identifiable intangible assets:
Total identifiable intangible assets			$ 2,000,000
Goodwill		$ 447,951	447,951
Estimated useful life		197 months
Trademarks [Member]
Identifiable intangible assets:
Total identifiable intangible assets			99,000
Customer base [Member]
Identifiable intangible assets:
Total identifiable intangible assets			37,000
Developed technology [Member]
Identifiable intangible assets:
Total identifiable intangible assets			$ 1,864,000
BDI [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	$ 17,000
Accounts receivable	21,000
Inventory	379,000
Prepaid and other assets	51,000
Equipment	1,000
Identifiable intangible assets:
Total identifiable intangible assets	2,000,000
Goodwill	430,000
Accounts payable	(118,000)
Accrued and other liabilities	(175,000)
Non-controlling interest	(29,000)
Purchase price	2,577,000
BDI [Member] | Trademarks [Member]
Identifiable intangible assets:
Total identifiable intangible assets	$ 99,000
Estimated useful life	5 years
BDI [Member] | Customer base [Member]
Identifiable intangible assets:
Total identifiable intangible assets	$ 37,000
Estimated useful life	6 years
BDI [Member] | Developed technology [Member]
Identifiable intangible assets:
Total identifiable intangible assets	$ 1,864,000
Estimated useful life	4 years

Acquisition and Discontinued 49

Acquisition and Discontinued Operations (Schedule of Intangible Assets Acquired) (Details)	Dec. 31, 2016USD ($)
Finite-Lived Intangible Assets [Line Items]
Total	$ 2,000,000
Less accumulated amortization	(148,264)
Net acquired intangibles	1,851,736
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Total	99,000
Customer base [Member]
Finite-Lived Intangible Assets [Line Items]
Total	37,000
Developed technology [Member]
Finite-Lived Intangible Assets [Line Items]
Total	$ 1,864,000

Acquisition and Discontinued 50

Acquisition and Discontinued Operations (Schedule of Assets and Liabilities related to Discontinued Operations) (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Total current assets	$ 11,532	$ 486,890
Current liabilities:
Total current liabilities	202,080	258,819
BDI [Member]
Current assets:
Accounts receivable	8,000	5,000
Inventories		416,000
Prepaid expenses	4,000	66,000
Total current assets	12,000	487,000
Equipment and furnishings, net		36,000
Intangible assets, net		2,281,000
Deposit		37,000
Total noncurrent assets		2,354,000
Current liabilities:
Accounts payable	37,000	174,000
Accrued expenses	28,000	85,000
Deferred revenue	137,000
Total current liabilities	$ 202,000	$ 259,000

Acquisition and Discontinued 51

Acquisition and Discontinued Operations (Summarized results of the discontinued operation) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Escrow forfeiture gain			$ 134,812
Impairment (loss)			(2,754,131)
BDI [Member]
Sales	7,000	$ 2,000	37,000	$ 2,000
Cost of sales	2,000		6,000
Gross margin	5,000		31,000
Operating expenses	(26,000)		975,000
Operating loss	31,000		(944,000)
Escrow forfeiture gain			135,000
Impairment (loss)			(2,754,000)
Income (loss) from discontinued operations	$ 31,000		$ (3,563,000)

Commitments and contingencies (

Commitments and contingencies (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)Officers	Sep. 30, 2016USD ($)	May 31, 2017USD ($)	Feb. 25, 2016USD ($)
Operating Leased Assets [Line Items]
Rent expense			$ 13,000
Sales price of corporate headquarters, land and building to a third party						$ 4,053,000
Proceeds from sale of property plant and equipment				$ 1,799,143
Gain from sale of property plant and equipment		$ 13,062		$ 1,933,335
BDI [Member]
Operating Leased Assets [Line Items]
Lease expiration date			Mar. 31, 2018
Future minimum operating lease commitments owed in 2017					$ 294,000
Rent expense			$ 216,000
Prepayment of rent					$ 80,419
Lease deposit			$ 37,000
Employment Contracts [Member]
Operating Leased Assets [Line Items]
Number of officers | Officers			1
Annual commitment amount	$ 272,000		$ 272,000
Subsidiary [Member]
Operating Leased Assets [Line Items]
Rent expense			$ 229,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Nov. 01, 2017	Oct. 20, 2017	Oct. 18, 2017	Oct. 10, 2017	Nov. 14, 2017	Sep. 30, 2017	Sep. 30, 2016
Subsequent Event [Line Items]
Proceeds from issuance of common stock						$ 1,913,509
Subsequent Event [Member]
Subsequent Event [Line Items]
Cash dividend			$ 9,562,000
Dividends paid, price per share				$ 1
Dividend declaration date			Oct. 2, 2017
Dividend record date			Oct. 13, 2017
Dividend payment date			Oct. 18, 2017
Subsequent Event [Member] | Tess Inc [Member]
Subsequent Event [Line Items]
Percentage of acquired entity		52.00%
Investment amount		$ 320,000
Net tangible assets acquired		$ 10,000
Subsequent Event [Member] | Tess Inc [Member] | Restricted Common Stock [Member]
Subsequent Event [Line Items]
Stock issued during period		75,000
Subsequent Event [Member] | Tess Inc [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Shares of subsidiary's common stock exchanged for company's restricted common stock		2,708,333
Number of common stock shares registered for resale through registration statement		25,000
Subsequent Event [Member] | Kairos Global Technology, Inc [Member]
Subsequent Event [Line Items]
Royalty percentage	40.00%
Subsequent Event [Member] | Kairos Global Technology, Inc [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of shares of common stock issuable upon conversion	1,750,001
Preferred stock stated value per share	$ 6.80
Conversion price	$ 6.80
Subsequent Event [Member] | Kairos Global Technology, Inc [Member] | Series B Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Stock issued for purchase of assets	1,750,001
Subsequent Event [Member] | March 2017 Private Offering Transaction One [Member] | Common Stock Offering [Member]
Subsequent Event [Line Items]
Total warrants exercised for cash during amendment period					420,000
Subsequent Event [Member] | March 2017 Private Offering Transaction One [Member] | Convertible Note Offering [Member]
Subsequent Event [Line Items]
Total warrants exercised for cash during amendment period					200,000
Subsequent Event [Member] | March 2017 Private Offering Transaction Two [Member]
Subsequent Event [Line Items]
Total warrants exercised for cash during amendment period					2,060,000
Subsequent Event [Member] | March 2017 Private Offering Transaction Two [Member] | Common Stock Offering [Member]
Subsequent Event [Line Items]
Amended exercise price of warrants					$ 3.50
Total warrants exercised for cash during amendment period					360,000
Subsequent Event [Member] | March 2017 Private Offering Transaction Two [Member] | Convertible Note Offering [Member]
Subsequent Event [Line Items]
Amended exercise price of warrants					$ 3.56
Total warrants exercised for cash during amendment period					1,700,000
Subsequent Event [Member] | Series A Preferred Stock
Subsequent Event [Line Items]
Preferred stock shares converted					8,284
Subsequent Event [Member] | Common Stock [Member] | March 2017 Private Offering Transaction One [Member]
Subsequent Event [Line Items]
Stock issued during period					620,000
Proceeds from issuance of common stock					$ 1,860,000
Conversion of stock					828,404
Subsequent Event [Member] | Common Stock [Member] | March 2017 Private Offering Transaction Two [Member]
Subsequent Event [Line Items]
Stock issued during period					1,228,690
Subsequent Event [Member] | Temporary Reduction in Warrant Exercise Price [Member]
Subsequent Event [Line Items]
Amended exercise price of warrants				$ 3
Total warrants covered by amended exercise price				2,800,000
Total warrants exercised for cash during amendment period				620,000